Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Sanegene Bio Usa Inc. is currently navigating the patent prosecution process within the Biotechnology & Pharmaceuticals technology area. The company has 2 pending office actions, indicating a focused but active engagement with the patent office. These actions are distributed across 2 distinct examiners, which prevents a single individual from controlling the entirety of the company's current patent pipeline and spreads the procedural risk.
The examination process is further divided across distinct art units. This separation suggests that the underlying technologies may fall into different regulatory or technical categories within the pharmaceutical sector. For the legal team, this requires managing separate tracks of communication and technical requirements, as each art unit may have different internal guidelines or timelines for reviewing biotechnology applications.
WARD, AARON DUREL is the busiest examiner for the portfolio, with 1 busiest examiner pending office action. Since the total number of pending actions is 2, WARD, AARON DUREL is responsible for one of these active matters. The remaining action is handled by another distinct examiner, ensuring that the prosecution progress is split between the 2 distinct art units involved in the review, which allows for parallel progress on different technical fronts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WARD, AARON DUREL | 1 | — | — |
| ALLEN, SARAH ELIZABETH | 1 | 57.1% | +50.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18366574 | DOUBLE STRANDED RNA TARGETING ANGIOTENSINOGEN (AGT) AND METHODS OF USE THEREOF | WARD, AARON DUREL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18350256 | OPTIMIZED 2'- MODIFIED RIBOSE DERIVATIVES AND METHODS OF USE | ALLEN, SARAH ELIZABETH | — |
| Art Unit | Apps |
|---|---|
| 1636 | 1 |
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18366574 | DOUBLE STRANDED RNA TARGETING ANGIOTENSINOGEN (AGT) AND METHODS OF USE THEREOF | WARD, AARON DUREL | 1636 | §101§103§112 | Non-Final OA | — | Pending | Aug 07, 2023 |
| 18350256 | OPTIMIZED 2'- MODIFIED RIBOSE DERIVATIVES AND METHODS OF USE | ALLEN, SARAH ELIZABETH | 1637 | §102§103§112DP | Non-Final OA | — | Pending | Jul 11, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial